Pfizer's plan to as much as quadruple U.S. prices for its COVID-19 vaccine next year is beyond Wall Street's expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far, analysts said.
  • sexy_peach@feddit.de
    11·
    2 years ago

    It would, but it would also slow their investment into new treatments, if everybody can just copy it.